Press release
Myopia Treatment Pipeline Shows Strong Momentum as 8+ Pharma Companies in the Race | DelveInsight
Curious about the latest updates in the Myopia Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/myopia-pipeline-insight [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Myopia Pipeline Report
* On January 09, 2026- IDB VisionCare SDN BHD conducted a clinical trial is designed to assess the efficacy and safety of Atropine Sulphate 0.025% w/v Eye Drops compared to placebo in a randomized, double-blind, placebo-controlled study for the management of myopia progression in children.
* DelveInsight's Myopia Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Myopia treatment.
* The leading Myopia Companies, such as Cloudbreak Pharma, Sunhawk Vision Biotech, Inc., iVeena Delivery Systems, Inc., Stuart Therapeutics and others.
* Promising Myopia Therapies such as SYD-101 Dose 1, Atropine sulfate eye drops 0.01%, Alleance Registered , Atropine Sulfate, Optifree Replenish, SHJ002, Atropine, Ranibizumab and others.
Want to know which companies are leading innovation in Myopia? Dive into the full pipeline insights @ Myopia Clinical Trials Assessment [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Myopia Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Myopia Pipeline Report also highlights the unmet needs with respect to the Myopia.
Myopia Overview
Myopia, also known as nearsightedness, is a common vision condition in which distant objects appear blurry while close objects can be seen clearly. It occurs when the eye grows too long from front to back or when the cornea is too curved, causing light rays to focus in front of the retina instead of directly on it. Myopia often begins in childhood and tends to progress into the teenage years, especially in cases where there is a strong genetic predisposition or environmental factors such as prolonged near work and limited outdoor activity.
Myopia Emerging Drugs Profile
* CBT-009: Cloudbreak Pharma
Atropine is a mydriatic agent, which clinically shows promising potential in treating progressive Myopia. Topical ophthalmic atropine sulfate has an extensive clinical history dating back several decades. Topical ophthalmic solution of 1% atropine sulfate has been approved worldwide for use in producing cycloplegia, mydriasis and in penalizing the healthy eye in treatment of amblyopia. CBT-009 is a novel ophthalmic formulation of atropine, which will substantially improve atropine stability in the formulation and ultimately product shelf life. Currently, the drug is in Phase III stage of its development for the treatment of Myopia.
* SHJ002: Sunhawk Vision Biotech, Inc.
SHJ002 is an investigational therapeutic being developed for the treatment of myopia, aimed at controlling the progression of axial elongation-a primary factor contributing to the condition. Designed as a topical formulation, SHJ002 targets key molecular pathways involved in scleral remodeling, potentially stabilizing the structural integrity of the eye. By addressing the biomechanical and biochemical changes that lead to myopic progression, SHJ002 offers a non-invasive approach with the potential to complement or enhance existing myopia management strategies such as optical correction and lifestyle modifications. Currently, the drug is in Phase II stage of its development for the treatment of Myopia.
* IVMED 85: iVeena Delivery Systems, Inc.
IVMED-85 is a daily eye drop that strengthens scleral and corneal collagen crosslinks through LOX activation, potentially leading to improved refraction and a decrease in the rate of axial elongation. It works by enhancing the activity of lysyl oxidase (LOX), an enzyme critical for stabilizing extracellular matrix proteins like collagen and elastin. This biochemical reinforcement increases the biomechanical strength of ocular tissues, reducing progressive deformation of the eye. By targeting the structural integrity of the sclera, IVMED-85 aims to slow or halt myopic progression at its root cause. Currently, the drug is in Phase I/II clinical studies for the treatment of Myopia.
If you're tracking ongoing Myopia Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Myopia Treatment Drugs [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Myopia Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of Myopia with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myopia Treatment.
* Myopia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Myopia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myopia market.
Myopia Companies
Cloudbreak Pharma, Sunhawk Vision Biotech, Inc., iVeena Delivery Systems, Inc., Stuart Therapeutics and others.
Myopia Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Myopia Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
From emerging drug candidates to competitive intelligence, the Myopia Pipeline Report covers it all - check it out now @ Myopia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Myopia Pipeline Report
* Coverage- Global
* Myopia Companies- Cloudbreak Pharma, Sunhawk Vision Biotech, Inc., iVeena Delivery Systems, Inc., Stuart Therapeutics and others.
* Myopia Therapies- SYD-101 Dose 1, Atropine sulfate eye drops 0.01%, Alleance Registered , Atropine Sulfate, Optifree Replenish, SHJ002, Atropine, Ranibizumab and others.
* Myopia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Myopia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Myopia Treatment landscape in this detailed analysis @ Myopia Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Myopia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Myopia- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* CBT-009: Cloudbreak Pharma
* Mid Stage Products (Phase II)
* SHJ002: Sunhawk Vision Biotech, Inc.
* Early Stage Products (Phase I/II)
* IVMED 85: iVeena Delivery Systems, Inc.
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Myopia Key Companies
* Myopia Key Products
* Myopia- Unmet Needs
* Myopia- Market Drivers and Barriers
* Myopia- Future Perspectives and Conclusion
* Myopia Analyst Views
* Myopia Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myopia-treatment-pipeline-shows-strong-momentum-as-8-pharma-companies-in-the-race-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/myopia-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myopia Treatment Pipeline Shows Strong Momentum as 8+ Pharma Companies in the Race | DelveInsight here
News-ID: 4351896 • Views: …
More Releases from ABNewswire
A US Startup Achieves Rapid Business Growth by Purchasing Toptrue Insulated Wate …
A US Startup Achieves Rapid Business Growth by Purchasing Toptrue Insulated Water Bottle [https://www.toptruebottle.com/water-bottle-tag/]s
From Garage Startup to Nationwide Bestseller: EcoKeep Partners with Toptrue to Achieve Explosive Business Growth with a Constant Temperature Solution
In the fiercely competitive US consumer market, countless startups are searching for the "key to success"-a product that meets user needs and a reliable supply chain. In 2021, EcoKeep, a startup that began in a California garage, achieved…
Retail data reveals: Cookware with tempered glass lids is more popular among con …
Retail data reveals: Cookware [https://www.proshuicookware.com/cookware-tag/] with tempered glass lids is more popular among consumers
Many buyers and brands have noticed that when comparing identical Cookware Set [https://www.proshuicookware.com/cookware-set-tag/]s, versions with tempered glass lids consistently sell out first. Both in physical stores and on cross-border e-commerce platforms, these pots achieve higher click-through rates and conversion rates. The question is: Can glass lids truly justify a purchase? Or are they merely a gimmick? After…
Acute Ischemic Stroke Pipeline 2025: Therapies, MOA Insights, and Key Clinical T …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acute Ischemic Stroke pipeline constitutes 20+ key companies continuously working towards developing 25+ Acute Ischemic Stroke treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Acute Ischemic Stroke Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
What if business goods are damaged? How can users successfully claim compensatio …
In the long river of cross-border trade and international logistics, even with the most sophisticated transportation solutions, the risk of cargo damage remains like a hidden minefield-sea storms, air turbulence, negligence during transshipment and handling, and unexpected customs inspections can all lead to damage, shortages, or spoilage of goods. For cross-border sellers and brands reliant on global supply chains, cargo damage not only means direct economic losses but can also…
More Releases for Myopia
Myopia Market Assessment & Forecast: Strategic Insights into Pediatric Myopia Ma …
Albany, United States - September 25, 2025 - DelveInsight, a leading provider of market intelligence and strategic consulting services in the healthcare sector, has released a comprehensive case study report on Myopia Market Assessment & Forecast, providing in-depth insights into the pediatric myopia landscape across Asia. This detailed study highlights prevalence trends, treatment paradigms, and market opportunities, equipping stakeholders with the actionable intelligence required to make informed decisions in the…
Myopia Control Lenses Market Forecast to Expand at 16.2% CAGR Amid Increasing Pe …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Myopia Control Lenses Market- (By Lens Type (Multifocal Lenses, Orthokeratology Lenses, Dual-Focus Lenses, Peripheral Defocus Lenses), By Age Group (Children, Adults), By Distribution Channel (Optometry Clinics, Optical Retail Stores, Online Retail)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the Global Myopia Control Lenses Market is valued…
Myopia Control Lenses Market Size to Grow with Rising Prevalence of Childhood My …
The latest Myopia Control Lenses Market research report offers crucial insights into how the industry is evolving, highlighting key drivers of growth and the main revenue streams expected between 2025 and 2032. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The Industry compass guiding business through the complexities of the market, presenting not only the current landscape but also the latest innovations shaping its…
Myopia Control Devices Market - Seeing Beyond Blur: Revolutionary Myopia Devices …
Newark, New Castle, USA: The "Myopia Control Devices Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Myopia Control Devices Market: https://www.growthplusreports.com/report/myopia-control-devices-market/7989
This latest report researches the industry structure,…
Myopia Control Devices Market - Unlocking the Future of Clear Sight: Myopia Cont …
Newark, New Castle, USA - new report, titled Myopia Control Devices Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Myopia Control Devices market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Myopia Control Devices market. The report offers an overview of…
The Myopia Market is expected to be driven by the factors such as the rising cas …
The Myopia market is expected to show positive growth, mainly attributed to the increased diagnosed prevalence and also, the launch of upcoming devices during the forecast period. Moreover, advances in disease mechanisms have yielded new diagnostic and treatment approaches, opening avenues to better treatment interventions.
The Myopia market report provides current treatment practices, emerging drugs, Myopia market share of the individual therapies, current and forecasted Myopia market Size from 2019 to…
